Clinical Trials

166 studies in Hematology - Enterprise

  1. A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
    1. Arizona
  2. A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
    1. Arizona
  3. Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: a Phase I Study
    1. Florida
    2. Minnesota
  4. Treatment of Children With All Stages of Hepatoblastoma
    1. Minnesota
  5. Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
    1. Arizona
    2. Minnesota
  6. A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
    1. Minnesota
  7. A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
    1. Florida
    2. Minnesota
  8. Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine
    1. Minnesota
  9. A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma
    1. Arizona
    2. Minnesota
  10. A COG Study for Collecting and Banking Ewing Sarcoma Specimens
    1. Minnesota
  1. Prev
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. Next

Clinical Trials

166 studies in Hematology - Enterprise

  1. A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
    1. Arizona
  2. A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
    1. Arizona
  3. Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: a Phase I Study
    1. Florida
    2. Minnesota
  4. Treatment of Children With All Stages of Hepatoblastoma
    1. Minnesota
  5. Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer
    1. Arizona
    2. Minnesota
  6. A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
    1. Minnesota
  7. A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
    1. Florida
    2. Minnesota
  8. Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine
    1. Minnesota
  9. A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma
    1. Arizona
    2. Minnesota
  10. A COG Study for Collecting and Banking Ewing Sarcoma Specimens
    1. Minnesota
  1. Prev
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5
  7. Next
.

Mayo Clinic Footer